Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerStrategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and marketPolymeric micelles in anticancer therapy: targeting, imaging and triggered release.Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendationsBioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® ELFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases.Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier.Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.Bioavailability of phytochemicals and its enhancement by drug delivery systems.The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: a Korean Gynecologic Oncology Group study (KGOG-3021)Nanomedicinal products: a survey on specific toxicity and side effects.Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.Nanoparticles and Controlled Delivery for Bioactive Compounds: Outlining Challenges for New "Smart-Foods" for Health.
P2860
Q24657308-E6D278B9-0D89-4102-8E29-944F32701CCDQ27015050-F6961694-FFBB-4056-AE73-815F1796CA3DQ30478123-75DC3A84-53AA-4F25-974D-7B88B64C7FC4Q33751197-5913FFD3-00B6-400A-AE78-0B6F07145896Q33982751-C94A126E-45FA-4B2B-AE0D-7B562112BE51Q34313613-6AD6D463-7171-49C6-81E1-E5E2D8452F63Q36138243-0D34D4D0-B2E1-43E9-B1A6-B16C344635C9Q36610814-6F6A58C9-3A41-4E01-A8A1-64D0AFCEEC22Q36678462-F6E6407D-B665-4834-B0D3-AE3680E20C40Q36680050-2B6CC38B-A322-415C-A373-A918F5F1103FQ36719714-DDEFA195-871B-47B8-B77E-41BCFA2DF779Q37469417-869058E3-F003-45B6-8CB3-B8CC4C20F860Q37669173-6C207471-9DCB-4EDA-815A-9A6524CA48AEQ38084084-0B5F03F2-33B2-4DF5-8BE7-768B0F7BF592Q38358625-0A51D200-8504-4A94-AB54-E175FAD7E2F0Q38889304-7C9CE3A0-1DD7-4260-9095-AB834F913234Q41545896-D1C38C2B-BBD6-4F33-AAAC-66159301BF51Q52688051-CAD20E94-F7B7-4282-BFFE-4C3779FF6536Q55252923-52B4DA6B-8C92-488F-9214-498C91CBEC37
P2860
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@ast
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@en
type
label
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@ast
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@en
prefLabel
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@ast
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@en
P2093
P2860
P356
P1476
Fatal outcome of a hypersensit ...... iew of premedication regimens.
@en
P2093
H Gelderblom
J P van Meerbeeck
J S Kloover
M A den Bakker
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601301
P407
P577
2004-01-01T00:00:00Z
P6179
1042290334